- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case T-381/21: Order of the General Court of 22 December 2021 — D&A Pharma v EMA (Action for annulment — Medicinal products for human use — Application for marketing authorisation for the medicinal product Hopveus — Non-renewal of a permanent scientific advisory group — No interest in bringing proceedings — Inadmissibility)
ECLI:EU:UNKNOWN:62021TB0381
62021TB0381
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
14.3.2022
Official Journal of the European Union
C 119/46
(Case T-381/21) (<span class="oj-super oj-note-tag">1</span>)
(Action for annulment - Medicinal products for human use - Application for marketing authorisation for the medicinal product Hopveus - Non-renewal of a permanent scientific advisory group - No interest in bringing proceedings - Inadmissibility)
(2022/C 119/65)
Language of the case: French
Parties
Applicant: Debregeas et associés Pharma (D&A Pharma) (Paris, France) (represented by: N. Viguié and D. Krzisch, lawyers)
Defendant: European Medicines Agency (represented by: C. Bortoluzzi, H. Kerr, S. Marino and S. Drosos, acting as Agents)
Re:
APPLICATION pursuant to Article 263 TFEU seeking annulment of the decision of EMA not to renew the scientific advisory group on psychiatry within the Committee for Human Medicinal Products, revealed implicitly by the public call for expression of interest for experts to become members of EMA’s scientific advisory groups and the press release of EMA of 5 May 2021.
Operative part of the order
1.The action is dismissed as being inadmissible.
2.There is no longer any need to adjudicate on the application for leave to intervene submitted by the European Parliament.
3.Debregeas et associés Pharma (D & A Pharma) shall pay the costs.
4.The Parliament shall bear its own costs relating to its application for leave to intervene.
(<span class="oj-super">1</span>) OJ C 329, 16.8.2021.